Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HBS-301

Small molecule · developed by Harmony Biosciences Management

Phase 3 Most advanced trial
HRMY Developer
2 Registered trials

What is HBS-301?

HBS-301 is a delayed-release formulation of pitolisant.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Harmony Biosciences Management, Inc. (HRMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07675135 Phase 3 EDS Recruiting HRMY
NCT07500090 Phase 3 Idiopathic Hypersomnia Recruiting HRMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CataplexyEDSFatigueIdiopathic HypersomniaNarcolepsy

More from Harmony Biosciences Management

Follow HRMY, the company behind HBS-301

See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.